CJC-1295 (No-DAC) and Ipamorelin at a glance
CJC-1295 (No-DAC) and Ipamorelin are two synthetic peptides catalogued together as a single co-formulated reference material for laboratory study. This profile sets out the chemical identity of each component, the physical description of the co-formulated specimen, and the analytical methods used to confirm that both peptides are present and to estimate the purity of each. Because the vial holds two distinct peptides rather than one, identity testing carries an extra step compared with a single-compound reference material, and that step is the focus of this profile. The co-formulated material is supplied here strictly as a reference material for in-vitro study. The product page is CJC-1295 (No-DAC) + Ipamorelin.
Ipamorelin: sequence and molecular identity
Ipamorelin is a synthetic pentapeptide, a chain of five amino-acid residues. Its sequence is written Aib-His-D-2-Nal-D-Phe-Lys-NH2, where Aib is 2-aminoisobutyric acid and D-2-Nal is D-2-naphthylalanine; the terminal NH2 indicates a C-terminal amide. Two of the five positions use D-configuration residues and one uses a non-standard residue, so Ipamorelin is not a simple chain of the twenty common amino acids. It is registered under CAS number 170851-70-4 and appears in PubChem as compound CID 9831659. The molecular formula is C38H49N9O5, corresponding to an average molecular weight of approximately 711.85 g/mol. These non-standard residues give Ipamorelin a distinctive mass that is straightforward to separate from its co-formulation partner by mass spectrometry.
CJC-1295 (No-DAC): a modified GRF(1-29) analog
CJC-1295 in its No-DAC form is a synthetic 29-residue peptide, an analog of the GRF(1-29) sequence carrying a small set of amino-acid substitutions that distinguish it from the native sequence. In the research literature the same material is also referred to as Modified GRF(1-29), or Mod GRF 1-29. The label No-DAC signals that this form does not carry the Drug Affinity Complex (DAC) modification found in the separate compound CJC-1295 (DAC); the two forms share a sequence origin but differ in mass, and are therefore different reference materials. Published sources most often record the No-DAC form with the molecular formula C152H252N44O42 and an average molecular weight near 3367.9 g/mol. Because the name CJC-1295 is used in the literature for both the DAC and No-DAC forms, the exact registry number and mass of a given specimen are confirmed by analysis and recorded on its Certificate of Analysis rather than assumed from the name.
Physical description and laboratory handling
As supplied, the co-formulated material is typically a lyophilised (freeze-dried) white to off-white powder containing both peptides. For laboratory handling, the dry solid is generally kept cold, dry, and shielded from light. When a solution is required for analytical work, the powder is dissolved in an appropriate laboratory solvent such as sterile water. Prepared solutions are commonly divided into aliquots and kept frozen, and repeated freezing and thawing of a single aliquot is usually avoided so that the measured identity and purity of each peptide are not affected by handling. These are storage and handling notes for a research specimen only.
Confirming identity and purity of a two-peptide co-formulation
Confirming a co-formulated reference material asks two questions at once: are both intended peptides present, and how pure is each. High-performance liquid chromatography (HPLC) separates the components of the sample. Because Ipamorelin and the CJC-1295 (No-DAC) peptide differ in size, charge, and hydrophobicity, reversed-phase HPLC resolves them as two separate peaks at different retention times. The area of each main peak relative to the total gives an estimated purity figure for that component, and the absence of unexpected additional peaks is part of the assessment. Identity is then confirmed by mass spectrometry. Liquid chromatography-mass spectrometry (LC-MS) couples the separation directly to a mass detector, and high-resolution mass spectrometry (HRMS) measures each intact mass precisely enough to match it against the theoretical value calculated from each peptide’s formula: close to 711.85 for Ipamorelin and near 3367.9 for the No-DAC peptide. A single blended purity number cannot, on its own, show that both peptides are present; matching two separate masses is what distinguishes a genuine two-component co-formulation from a single peptide or an unexpected species. The two analytical techniques are compared in HPLC versus mass spectrometry.
University-core testing and the Certificate of Analysis
Every batch of this co-formulated material supplied here is characterised for identity and purity at the USC Alfred E. Mann Multi-Omics Mass Spectrometry Core, a university laboratory, using LC-MS and HRMS. For a blend this matters more than for a single compound, because two masses have to be confirmed rather than one. The resulting Certificate of Analysis is published rather than kept on request, so the analytical basis for the label can be checked. A certificate for a co-formulation generally reports the observed mass of each peptide against its theoretical value, a main-peak percentage, a batch or lot number tying the result to one production run, and the instrument and method used. Further detail on reading these documents is set out in the guide on how to read a peptide Certificate of Analysis. Collected certificates are held in the COA library.
Where this co-formulation sits in the catalogue
CJC-1295 (No-DAC) + Ipamorelin is one of the co-formulated reference materials in the catalogue, alongside other multi-component specimens. Each component here is also studied individually in the wider literature, and Ipamorelin and the GRF(1-29) analogs are frequently referenced together as synthetic peptides of research interest. A related single-component synthetic analog catalogued separately is Tesamorelin. For a laboratory sourcing a two-peptide reference material, the practical points from this profile are that the vial holds two distinct masses, that both are confirmed independently by mass spectrometry, and that the per-batch certificate records each figure.
For laboratory research use only. Not for human or veterinary use.
Frequently asked questions
What is in a CJC-1295 (No-DAC) + Ipamorelin co-formulation?
It is a single reference material containing two synthetic peptides: Ipamorelin, a pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 (CAS 170851-70-4), and CJC-1295 in its No-DAC form, a 29-residue analog of the GRF(1-29) sequence also called Modified GRF 1-29. The two are catalogued and supplied together as one co-formulated specimen for laboratory study.
What are the molecular weights of the two peptides?
Ipamorelin has the molecular formula C38H49N9O5 and an average molecular weight of approximately 711.85 g/mol (PubChem CID 9831659). The CJC-1295 (No-DAC) peptide is most often recorded with the formula C152H252N44O42 and an average molecular weight near 3367.9 g/mol. The two masses are far enough apart that mass spectrometry distinguishes them without difficulty.
How is a two-peptide co-formulation tested for identity and purity?
Reversed-phase HPLC resolves the two peptides as two separate peaks, and the area of each peak relative to the total gives an estimated purity figure for that component. Mass spectrometry (LC-MS and HRMS) then confirms each peptide independently by matching its observed intact mass to the theoretical value from its formula. Each batch supplied here is tested at the USC Alfred E. Mann Multi-Omics Mass Spectrometry Core, with a published Certificate of Analysis.
What is the difference between the DAC and No-DAC forms of CJC-1295?
The No-DAC form does not carry the Drug Affinity Complex (DAC) modification present in the separate compound CJC-1295 (DAC). The two forms share the GRF(1-29) sequence origin but differ in mass, so they are different reference materials. Because the name CJC-1295 is used for both, the exact mass and registry number of a specimen are confirmed by analysis and recorded on its Certificate of Analysis.
How should a co-formulated peptide reference material be stored?
It is typically supplied as a lyophilised white to off-white powder and generally kept cold, dry, and away from light. When a solution is needed for analytical work, the powder is dissolved in an appropriate laboratory solvent such as sterile water, divided into aliquots, and kept frozen, with repeated freezing and thawing of one aliquot usually avoided. These are handling notes for a research specimen only.